NCT01646827View on ClinicalTrials.gov

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
Schizophrenia
Interventions
DRUG

Aripiprazole IM Depot

One injection of 400 mg aripiprazole IM depot

Trial Locations (6)

20016

Comprehensive Clinical Development, Inc., Washington D.C.

78754

Community Clinical Research, Inc., Austin

90703

Comprehensive Clinical Development, Inc., Cerritos

92102

CNRI - San Diego, San Diego

92701

Neuropsychiatric Research Center of Orange County, Santa Ana

92845

Collaborative Neuroscience Network, Inc., Garden Grove

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01646827 - An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter